Abstract: The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound healing. The disclosure also includes pharmaceutical compositions comprising the multimers, including compositions suitable for topical or systemic administration.

Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.

Abstract: The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound healing. The disclosure also includes pharmaceutical compositions comprising the multimers, including compositions suitable for topical or systemic administration.

Abstract: The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound healing. The disclosure also includes pharmaceutical compositions comprising the multimers, including compositions suitable for topical or systemic administration.

Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof

Abstract: The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound healing. The disclosure also includes pharmaceutical compositions comprising the multimers, including compositions suitable for topical or systemic administration.

Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)?—[O—(CH2)?]?—O?—(CH2)?—Y— wherein ?, ?, ?, ?, and ? are each integers whose values are independently selected.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)?—[O—(CH2)?]?—O?—(CH2)?—Y— wherein ?, ?, ?, ?, and ? are each integers whose values are independently selected.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)?—[O—(CH2)?]?—O?—(CH2)?—Y— wherein ?, ?, ?, ?, and ? are each integers whose values are independently selected.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.